Drug and disease signature integration identifies synergistic combinations in glioblastoma

Drug and disease signature integration identifies synergistic combinations in glioblastoma

Inherent or acquired resistance to treatment of glioblastoma (GBM) is nearly universal. Here, the authors introduce a platform to identify synergistic drug combinations for patient-specific treatment of GBM based on gene expression signatures and small molecule perturbation-response profiles.

Guardado en:
Detalles Bibliográficos
Autores principales: Vasileios Stathias, Anna M. Jermakowicz, Marie E. Maloof, Michele Forlin, Winston Walters, Robert K. Suter, Michael A. Durante, Sion L. Williams, J. William Harbour, Claude-Henry Volmar, Nicholas J. Lyons, Claes Wahlestedt, Regina M. Graham, Michael E. Ivan, Ricardo J. Komotar, Jann N. Sarkaria, Aravind Subramanian, Todd R. Golub, Stephan C. Schürer, Nagi G. Ayad
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/27c294a5f7c843d6a3a8dc34a08977c6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Inherent or acquired resistance to treatment of glioblastoma (GBM) is nearly universal. Here, the authors introduce a platform to identify synergistic drug combinations for patient-specific treatment of GBM based on gene expression signatures and small molecule perturbation-response profiles.

Ejemplares similares